Neurizon has announced positive preclinical data regarding NUZ-001

Neurizon Therapeutics Limited (ASX: NUZ) announced that Dr. Michael Thurn, the company's managing director and CEO, delivered a compelling presentation today at the prestigious 7th Annual ALS Research Symposium hosted by ALS ONE. This significant event unites top global experts, patients, and advocates to discuss groundbreaking advancements in Amyotrophic Lateral Sclerosis research and treatment strategies.

In his presentation titled Exploring the Benefits of mTOR Inhibition in Patients with Amyotrophic Lateral Sclerosis, Dr. Thurn showcased Neurizon's latest preclinical findings on its lead candidate, NUZ-001. These promising results illustrate the potential of NUZ-001 as an mTOR inhibitor designed to enhance neuronal health and effectively slow disease progression. With its compelling therapeutic promise, NUZ-001 stands out as a pivotal player in the urgent fight against ALS.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com